| Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder. | |
| | |
MedLine Citation:
|
PMID: 23330767 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate the growth and pubertal attainment of boys with attention deficit hyperactivity disorder (ADHD) on stimulant medication. DESIGN, SETTING AND PARTICIPANTS: Longitudinal study of boys aged 12.00-15.99 2013s at recruitment in 2005-2011, with stimulant-treated ADHD for at least 3 2013s, attending three paediatric practices (subjects), compared with longitudinal data from 174 boys from the Nepean longitudinal study (controls). MAIN OUTCOME MEASURES: Subjects' growth parameters before treatment were compared with controls aged 7 or 8 2013s; growth parameters and longitudinal changes on treatment to ages 12.00-13.99 and 14.00-15.99 2013s were compared with controls reviewed at 13 and 15 2013s of age, respectively. The subjects' pubertal staging and height velocity were related to their treatment history. RESULTS: Sixty-five subjects were recruited; mean duration of treatment was 6.3 ± 1.9 2013s. At baseline, their growth parameters were not significantly different from those of the controls after adjusting for age. Compared with the controls, after adjusting for current age and baseline growth parameter z score, subjects aged 12.00-13.99 2013s had significantly lower weight and body mass index (P < 0.01), and those aged 14.00-15.99 2013s had significantly lower height and weight (P < 0.05). At 12.00-13.99 2013s of age, the subjects were comparable to the controls in their pubertal development adjusted for age, but those aged 14.00-15.99 2013s reported significant delay (mean Tanner stage, 3.6 for subjects v 4.0 for controls; P < 0.05). The dose of medication was inversely correlated with the height velocity from baseline to 14.00-15.99 2013s of age (P < 0.05). CONCLUSIONS: Prolonged treatment (more than 3 2013s) with stimulant medication was associated with a slower rate of physical development during puberty. To maintain adequate height velocity during puberty, we recommend keeping the dose as low as possible. |
| | |
Authors:
|
Alison S Poulton; Elaine Melzer; Paul R Tait; Sarah P Garnett; Chris T Cowell; Louise A Baur; Simon Clarke |
Related Documents
:
|
17314727 - Cannabis and anxiety and depression in young adults: a large prospective study. 22956867 - Testosterone replacement therapy among elderly males: the testim registry in the us (tr... 9460837 - Use of minor tranquilizers among norwegian physicians. a nation-wide comparative study. 19010657 - A profile of adolescent cocaine use in northern ireland. 22551657 - Interaction between age and aerobic fitness in determining heart rate dynamics. 20488887 - Midlife psychological stress and risk of dementia: a 35-year longitudinal population st... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Medical journal of Australia Volume: 198 ISSN: 1326-5377 ISO Abbreviation: Med. J. Aust. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-01-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0400714 Medline TA: Med J Aust Country: Australia |
Other Details:
|
Languages: eng Pagination: 29-32 Citation Subset: IM |
Affiliation:
|
Sydney Medical School Nepean, University of Sydney, Sydney, NSW, Australia. alison.poulton@sydney.edu.au. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: National Heart Foundation of Australia consensus statement on catheter ablation as a therapy for atr...
Next Document: Male reproductive health disorders among Aboriginal and Torres Strait Islander men: a hidden problem...